Please login to the form below

Not currently logged in
Email:
Password:

tasimelteon

This page shows the latest tasimelteon news and features for those working in and with pharma, biotech and healthcare.

BMS' Opdivo backed as melanoma therapy in EU

BMS' Opdivo backed as melanoma therapy in EU

Vanda Pharmaceuticals got the go-ahead for Hetlioz (tasimelteon) for the treatment of non-24-hour sleep wake disorder in totally blind adults - which was approved in the US last year -

Latest news

  • FDA approves sleep disorder drug for blind people FDA approves sleep disorder drug for blind people

    Vanda Pharmaceuticals is now allowed to market its drug Hetlioz (tasimelteon) to treat a condition called non-24-hour sleep-wake disorder, which causes problems in the sleep cycle of blind

  • FDA panel backs sleep pattern drug for blind FDA panel backs sleep pattern drug for blind

    A Food Drug and Administration (FDA) advisory committee voted unanimously to recommend approval of Vanda Pharmaceuticals' Hetlioz (tasimelteon) for non-24-hour disorder (N24) in the totally blind. ... Tasimelteon acts on melatonin MT1/MT2 receptors and

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics